- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Analysis of persistence rate of cognitive enhancers in Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7737;
Also, donepezil and memantine were associated with longer persistence than rivastigmine and galantamine and choline alfocerate. In particular, in case of Nootropics, a high rate of initial prescription is given to patients with dementia, but rate of continuous prescription is not high.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, Namzaric (memantine ER/donepezil) / AbbVie, Supernus Pharma
Comparative evaluation of FDA-approved drugs for managing the symptoms of AD (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7528;
Although there are disease modifying drugs target the amyloids such as Aducanumab and Lecanemab, high costs (around $30,000/year) and severe side effects make them unfavorable for many patients suffering from AD. MCDM methods can be used as a decision-aid system for evaluating AD drugs and this study can be extended including more criteria and new drugs as they become available.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Symptomatic Alzheimer's Disease Therapy Utilization in 3 National Cohorts (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_6792;
Time on first therapy was relatively short (<1 year) and the majority of patients did not utilize a second therapy. These results underscore the unmet need for additional therapies to alleviate the significant burden of AD.
- |||||||||| memantine / Generic mfg.
Strategies for managing patients with moderate to severe Alzheimer (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_6713;
Although not statistically significant, treatment responses showed some differences. Patients who had shown good response at the time of the initial therapy of donepezil preferred higher-dose donepezil over memantine combination, whereas those who did not respond to the initial donepezil had more effective after memantine was added.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Drug utilization among patients with mild cognitive impairment and Alzheimer (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_6679;
The proportion of MCI and/or AD cases with prescriptions were similar across genders. The proportion with prescriptions was generally lowest among African Americans.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Analysis of persistence rate of cognitive enhancers in Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5671;
Also, donepezil and memantine were associated with longer persistence than rivastigmine and galantamine and choline alfocerate. In particular, in case of Nootropics, a high rate of initial prescription is given to patients with dementia, but rate of continuous prescription is not high.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, Namzaric (memantine ER/donepezil) / AbbVie, Supernus Pharma
Comparative evaluation of FDA-approved drugs for managing the symptoms of AD (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5462;
Although there are disease modifying drugs target the amyloids such as Aducanumab and Lecanemab, high costs (around $30,000/year) and severe side effects make them unfavorable for many patients suffering from AD. MCDM methods can be used as a decision-aid system for evaluating AD drugs and this study can be extended including more criteria and new drugs as they become available.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Analysis of persistence rate of cognitive enhancers in Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3425;
Also, donepezil and memantine were associated with longer persistence than rivastigmine and galantamine and choline alfocerate. In particular, in case of Nootropics, a high rate of initial prescription is given to patients with dementia, but rate of continuous prescription is not high.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, Namzaric (memantine ER/donepezil) / AbbVie, Supernus Pharma
Comparative evaluation of FDA-approved drugs for managing the symptoms of AD (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3216;
Although there are disease modifying drugs target the amyloids such as Aducanumab and Lecanemab, high costs (around $30,000/year) and severe side effects make them unfavorable for many patients suffering from AD. MCDM methods can be used as a decision-aid system for evaluating AD drugs and this study can be extended including more criteria and new drugs as they become available.
- |||||||||| memantine / Generic mfg.
GRIN2B genotypes and APOE haplotypes affect the age at onset of Alzheimer (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1749;
Genotypes of rs3764028 and APOE haplotypes are associated with the age at onset of AD, as well as with variations in dementia staging according to the use of Memantine. (Supported by FAPESP grant #2015/10109-5)
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Analysis of persistence rate of cognitive enhancers in Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1205;
Also, donepezil and memantine were associated with longer persistence than rivastigmine and galantamine and choline alfocerate. In particular, in case of Nootropics, a high rate of initial prescription is given to patients with dementia, but rate of continuous prescription is not high.
- |||||||||| Aduhelm (aducanumab) / Eisai, Biogen, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, Namzaric (memantine ER/donepezil) / AbbVie, Supernus Pharma
Comparative evaluation of FDA-approved drugs for managing the symptoms of AD (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_996;
Although there are disease modifying drugs target the amyloids such as Aducanumab and Lecanemab, high costs (around $30,000/year) and severe side effects make them unfavorable for many patients suffering from AD. MCDM methods can be used as a decision-aid system for evaluating AD drugs and this study can be extended including more criteria and new drugs as they become available.
- |||||||||| memantine / Generic mfg.
Review, Journal: Recognition and Management of the Long-term Effects of Cranial Radiation. (Pubmed Central) - Jun 19, 2023
Hippocampal-sparing intensity modulated radiotherapy and memantine represent effective interventions to avoid damage to regions of adult neurogenesis...Radiation-induced injury of the cataract and optic system can develop when these structures receive an amount of radiation that exceeds their tolerance. Special attention should always be paid to avoid irradiation of these sensitive structures, if possible, or minimize their dose to the lowest limit.
- |||||||||| memantine / Generic mfg.
Journal: Ethnic disparities in the uptake of anti-dementia medication in young and late-onset dementia. (Pubmed Central) - Jun 19, 2023
Special attention should always be paid to avoid irradiation of these sensitive structures, if possible, or minimize their dose to the lowest limit. Findings highlight the impact of social factors on current usage of anti-dementia medication and the need for more resources to enable equitable use of anti-dementia medication.
- |||||||||| ifenprodil tartrate / Chiba University Hospital, Nectiv (traxoprodil) / Pfizer
Journal: Binding Affinity and Mechanisms of Potential Antidepressants Targeting Human NMDA Receptors. (Pubmed Central) - Jun 14, 2023
We further compared S-ketamine and its chiral molecule, R-ketamine, and found that R-ketamine had a stronger binding capacity to the NMDA receptor. This study provides a computational reference for the treatment of depression targeting NMDA receptors, and the proposed results will provide potential strategies for further antidepressant development and is a useful resource for the future discovery of fast-acting antidepressant candidates.
- |||||||||| memantine / Generic mfg.
Journal: Memantine induced encephalopathy in chronic kidney disease: a case report. (Pubmed Central) - Jun 13, 2023
This study provides a computational reference for the treatment of depression targeting NMDA receptors, and the proposed results will provide potential strategies for further antidepressant development and is a useful resource for the future discovery of fast-acting antidepressant candidates. No abstract available
- |||||||||| ketamine / Generic mfg., memantine / Generic mfg.
Review, Journal: The NMDA receptor antagonists memantine and ketamine as anti-migraine agents. (Pubmed Central) - Jun 8, 2023
Particular attention should be paid to people who have a treatment-resistant form of migraine with aura or have exhausted existing treatment options. For them, the drugs under discussion could represent an interesting alternative in the future.
- |||||||||| memantine / Generic mfg.
Journal: CNS4 causes subtype-specific changes in agonist efficacy and reversal potential of permeant cations in NMDA receptors. (Pubmed Central) - Jun 7, 2023
CNS4 does not affect the activity of competitive antagonist binding at glycine (DCKA) and glutamate (DL-AP5) sites; however, it decreases memantine potency in 1/2A receptors but not in 1/2D receptors...Together, these findings reveal that CNS4 sensitizes ambient agonists and allosterically modulates agonist efficacy by altering Na permeability based on the GluN2 subunit composition. Overall, the pharmacology of CNS4 aligns with the need for drug candidates to treat hypoglutamatergic neuropsychiatric conditions such as loss function GRIN disorders and anti-NMDA receptor encephalitis.
- |||||||||| memantine / Generic mfg.
Clinical guideline, Review, Journal: A Systematic Review of Clinical Practice Guidelines for Alzheimer's Disease and Strategies for Future Advancements. (Pubmed Central) - Jun 1, 2023
Regular evidence-based updates of existing guidelines for the AD continuum are required over the coming decades to integrate rapidly evolving technologic and medical scientific advances and bring emerging approaches for management of early disease into clinical practice. This will pave the way toward biomarker-guided identification and targeted treatment and the realization of precision medicine for AD.
- |||||||||| Novel GRIN2D Variation in a baby with Epileptic Encephalopathy and Response to NMDA Receptor Channel Blocker-a Case Report (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_464;
She was started on sodium valproate, clobazam, phenobarbitone, lamotrigione and levetiracetam sequentially which failed to achieve seizure control...Adjunctive therapy with memantine and prednisolone showed marked clinical improvement...It demonstrates the importance of early genetic testing and functional evaluation of mutations. It also highlights the potential for individualized treatment guided by molecular genetics.
- |||||||||| Review, Journal: Mood Stabilizers of First and Second Generation. (Pubmed Central) - May 27, 2023
The article presents clinical experiences with mood stabilizers of the first and second generations and with "insufficient" ones. Further, current suggestions for their use in preventing recurrences of bipolar mood disorder are provided.
- |||||||||| memantine / Generic mfg.
Preclinical, Journal: Unfavorable effects of memantine on the skeletal system in female rats. (Pubmed Central) - May 25, 2023
No other effects on bone were observed in the memantine-treated OVX rats. In conclusion, the results of the present study indicated slight damaging skeletal effects of memantine in rats with normal estrogen levels.
- |||||||||| memantine / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date, Surgery: Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD) (clinicaltrials.gov) - May 25, 2023
P1, N=20, Active, not recruiting,
In conclusion, the results of the present study indicated slight damaging skeletal effects of memantine in rats with normal estrogen levels. Suspended --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Review, Journal: Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs. (Pubmed Central) - May 24, 2023
Herbal and food intake is also important as preventive strategy and recently focus has also been placed on herbal drugs for treatment. This review focuses on the molecular aspects, pathogenesis and recent studies that signifies the potential of medicinal plants and their extracts or chemical constituents for the treatment of degenerative symptoms related to AD.
- |||||||||| metformin / Generic mfg., tetracycline / Generic mfg., memantine / Generic mfg.
Biomarker, Clinical, Review: Effects of early adjunctive pharmacotherapy on serum levels of brain injury biomarkers in patients with traumatic brain injury: a systematic review of randomized controlled studies. (Pubmed Central) - May 22, 2023
Finally, employing stratified randomization in future clinical trials concerning potential confounders, including age, trauma severity levels, and type, is crucial to inform clinical decisions. Clinical Trial Registration: [https://www.crd.york.ac.uk/prospero/dis], identifier [CRD42022316327].
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Journal: Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs) (Pubmed Central) - May 21, 2023
In Japan, DMTs have not yet been approved for treating AD; however, four drugs are currently available for symptomatic therapies, including cholinesterase inhibitors (ChEIs) such as donepezil for mild-to-severe dementia, galantamine and rivastigmine for mild-to-moderate dementia, and memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, for moderate-to-severe dementia. In this review, we describe the use of four symptomatic anti-AD drugs in clinical practice for AD.
- |||||||||| galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Journal, Adverse events: Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database. (Pubmed Central) - May 20, 2023
Bradycardia, loss of consciousness, falls, and syncope incidence were significantly diverse. The Kaplan-Meier curve results for the cumulative ADEs incidence showed that donepezil had the slowest onset, while galantamine, rivastigmine, and memantine had approximately the same timing of onset.
- |||||||||| ketamine / Generic mfg.
The Use of Ketamine in Addressing Pediatric Treatment-Refractory OCD (Hall B Foyer, Exhibition Level Moscone South) - May 17, 2023 - Abstract #APA2023APA_787;
Thus, the short-term modulation of glutamatergic synaptic transmission by memantine and subsequent activation of Group III mGluR significantly affected the dynamics of neurodegeneration in the hippocampus. L
- |||||||||| memantine / Generic mfg., escitalopram / Generic mfg.
Neurocognitive Deficits Associated With Low Level Exposure to Solvents. a Case Report: Nail Salon Dementia (Hall B Foyer, Exhibition Level Moscone South) - May 17, 2023 - Abstract #APA2023APA_771;
For his memory deficits, he was initially started on Memantine 5 mg and then titrated to 10 mg...It has been hypothesized that this unique and often vulnerable population may have significant exposures to chemicals such as dibutyl phthalate (Park et al, 2021). In this poster, we hope to add to the much-needed discussion on occupational exposures via a case report on this patient.
|
